This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Locasciulli A, Bruno B, Alessandrino EP, Meloni G, Arcese W, Bandini G et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 2003; 31: 295–300.
Ivantes CAP, Amarante H, Ioshii SO, Pasquini R . Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant 2004; 33: 1181–1185.
Ljungman P, Locasciulli A, de Soria VG, Bekassy AN, Brinch L, Espigado I et al. Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy. Bone Marrow Transplant 2011; 47: 1217–1221.
Peffault de Latour R . Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004; 103: 1618–1624.
Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology (Baltimore, MD) 1999; 29: 1893–1899.
Castellino S, Lensing S, Riely C, Rai SN, Davila R, Hayden RT et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort. Blood 2004; 103: 2460–2466.
AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932–954.
Peffault de Latour R, Asselah T, Lévy V, Scieux C, Devergie A, Ribaud P et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2005; 36: 709–713.
Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756–1765.
Torres HA, Chong PP, de Lima M, Friedman MS, Giralt S, Hammond SP et al. Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. Biol Blood Marrow Transplant 2015; 21: 1870–1882.
Rehermann B . Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119: 1745–1754.
Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98: 706–714.
Scheel TKH, Rice CM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837–849.
Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002; 99: 15669–15674.
Acknowledgements
We would like to acknowledge and thank Lisa Beattie for her clinical support and Shane Cross for his pharmacology expertise. This work has been funded by NIH 5 P30CA02176536, American Association for Cancer Research, St. Baldrick’s Foundation, Assisi Foundation of Memphis, Individual Biomedical Research Award from The Hartwell Foundation and American Lebanese Syrian Associated Charities.
Author contributions
Conception and design: MHD; financial support: MHD and PT; provision of study material or patients: PT, TS and MHD; collection and assembly of data: TS and MHD; data analysis and interpretation: TS, MHD and PT; and manuscript writing: all authors. Final approval of manuscript: all authors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Thomas, P., Santiago, T. & Dallas, M. Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation. Bone Marrow Transplant 51, 735–737 (2016). https://doi.org/10.1038/bmt.2015.309
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.309